Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG.

Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25440788
2.
3.

Direct oral anticoagulants in acute coronary syndrome.

Ahrens I, Bode C.

Semin Hematol. 2014 Apr;51(2):147-51. doi: 10.1053/j.seminhematol.2014.03.004. Epub 2014 Mar 29.

PMID:
24861799
4.

Acute coronary syndromes: advances in antithrombotics.

Gukathasan N, Mehran R.

Curr Atheroscler Rep. 2013 Apr;15(4):318. doi: 10.1007/s11883-013-0318-8. Review.

PMID:
23456409
5.
6.

Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

Kar S, Bhatt DL.

Coron Artery Dis. 2012 Sep;23(6):380-90. doi: 10.1097/MCA.0b013e328356490a. Review.

PMID:
22728913
7.

Improving long-term ACS management: is there a role for the new antiplatelets?

Cohen M.

J Interv Cardiol. 2012 Oct;25(5):425-32. doi: 10.1111/j.1540-8183.2012.00738.x. Epub 2012 May 11. Review.

PMID:
22574644
8.

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; Coordinating Committee.

J Am Coll Cardiol. 2012 Apr 17;59(16):1413-25. doi: 10.1016/j.jacc.2012.02.008. Review.

9.

Anticoagulant agents in acute coronary syndromes.

Sakhuja R, Yeh RW, Bhatt DL.

Curr Probl Cardiol. 2011 Apr;36(4):127-68. doi: 10.1016/j.cpcardiol.2011.03.003. Review.

PMID:
21586352
10.

New-onset atrial fibrillation and acute coronary syndrome.

Lau DH, Alasady M, Brooks AG, Sanders P.

Expert Rev Cardiovasc Ther. 2010 Jul;8(7):941-8. doi: 10.1586/erc.10.61. Review.

PMID:
20602555
11.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
12.

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.

Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26.

13.

Prevention of cardiovascular events after acute coronary syndrome.

Wallentin L.

Semin Vasc Med. 2005 Aug;5(3):293-300. Review.

PMID:
16123917
14.

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nyström P, Bylock A; ESTEEM Investigators.

Lancet. 2003 Sep 6;362(9386):789-97.

PMID:
13678873
15.

[Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists].

Kondo K.

Nihon Yakurigaku Zasshi. 2000 Nov;116(5):263-8. Review. Japanese.

PMID:
11215375
16.
17.

[Drug therapy of acute myocardial infarction and unstable coronary syndrome].

Gjesdal K, Aursnes I.

Tidsskr Nor Laegeforen. 1990 Sep 10;110(21):2774-7. Norwegian.

PMID:
1977206
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk